Clinical characteristics and laboratory results of pregnant women with COVID-19 in Wuhan, China

Int J Gynaecol Obstet. 2020 Sep;150(3):312-317. doi: 10.1002/ijgo.13265. Epub 2020 Jul 3.

Abstract

Objective: To evaluate the clinical characteristics and laboratory test results in pregnant women with coronavirus disease 2019 (COVID-19).

Methods: A retrospective study to review and compare clinical data including electronic medical records and laboratory tests from pregnant and nonpregnant patients admitted the Central Hospital of Wuhan, China from December 8, 2019 to April 1, 2020.

Results: A total of 72 women (30 pregnant and 42 nonpregnant) with COVID-19 were included. No patients developed severe pneumonia during the study. Compared with the nonpregnant group, pregnant patients were admitted to hospital earlier (0.25 vs 11.00 days; P<0.001), presented milder symptoms, had a higher rate of asymptomatic infection (26.7% vs 0%), and shorter length of hospital stay (14.5 vs 17.0 days; P<0.01). Laboratory test results showed that levels of inflammation markers such as white blood cell count, neutrophil count and percentage, C-reactive protein, procalcitonin, and D-dimer were significantly higher in pregnant women, whereas mean lymphocyte percentage was significantly lower compared with nonpregnant women.

Conclusion: In some respects, the clinical characteristics and laboratory test results of COVID-19 in pregnant patients seems to be distinctive from their nonpregnant counterparts. Appropriate advice and positive treatment might be critical to the prognosis when dealing with these pregnant patients. Pregnant patients with COVID-19 had their own positive clinical characteristics and special laboratory test results. Responsive medical advice and active treatment for those patients are critical to recovery.

Keywords: COVID-19; China; Clinical characteristics; Coronavirus; Laboratory tests; Pregnancy; SARS-Cov-2.

MeSH terms

  • Adult
  • COVID-19 / blood
  • COVID-19 / diagnosis*
  • COVID-19 Testing / blood
  • COVID-19 Testing / diagnosis*
  • Case-Control Studies
  • Coronavirus
  • Female
  • Fibrin Fibrinogen Degradation Products / analysis
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious / blood
  • Pregnancy Complications, Infectious / diagnosis*
  • Pregnant Women
  • Procalcitonin / blood
  • Retrospective Studies
  • SARS-CoV-2*

Substances

  • Fibrin Fibrinogen Degradation Products
  • Procalcitonin
  • fibrin fragment D